Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843092 | 0.70 | GRIN2D (0.35) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL546127 | 0.69 | CYP2C9 (0.39) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL16554143 | 0.67 | LMNA (0.32) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4329163 | 0.67 | LMNA (0.32) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1015951 | 0.67 | GRIN2D (0.38) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25338011 | 0.67 | GRIN2D (0.38) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL678264 | 0.67 | GRIN2D (0.33) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL1015666 | 0.65 | LMNA (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10574918 | 0.64 | GRIN2D (0.38) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1592795 | 0.64 | GRIN2D (0.31) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065762-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065762-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | EPHX2 3743/4885GRIN2D 1890/4885GRIN3B 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.